AquaBounty Technologies, Inc. (NASDAQ:AQB) Sees Large Decrease in Short Interest

AquaBounty Technologies, Inc. (NASDAQ:AQB) was the recipient of a large decline in short interest in November. As of November 30th, there was short interest totalling 67,800 shares, a decline of 14.4% from the November 15th total of 79,200 shares. Based on an average daily volume of 26,300 shares, the short-interest ratio is presently 2.6 days. Approximately 1.9% of the company’s shares are short sold.

AquaBounty Technologies Stock Down 6.7 %

Shares of AQB traded down $0.04 on Friday, reaching $0.57. The stock had a trading volume of 166,398 shares, compared to its average volume of 31,082. The firm has a market capitalization of $2.21 million, a price-to-earnings ratio of -0.03 and a beta of 1.10. The company has a 50-day simple moving average of $1.05 and a 200-day simple moving average of $1.30. AquaBounty Technologies has a 12-month low of $0.56 and a 12-month high of $3.00. The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.98 and a current ratio of 3.02.

AquaBounty Technologies (NASDAQ:AQB) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.88) earnings per share for the quarter, hitting the consensus estimate of ($0.88). AquaBounty Technologies had a negative return on equity of 18.20% and a negative net margin of 5,842.69%. The company had revenue of $0.05 million for the quarter, compared to the consensus estimate of $0.10 million. During the same quarter in the prior year, the business posted ($1.60) EPS. Sell-side analysts predict that AquaBounty Technologies will post -4.86 EPS for the current year.

AquaBounty Technologies Company Profile

AquaBounty Technologies, Inc, a biotechnology company, operates in the aquaculture industry in the United States and Canada. The company engages in genetic, genomic, and fish health and nutrition research activities. It also operates salmon farms using proprietary technology. In addition, the company offers AquAdvantage Salmon, a genetically engineered Atlantic salmon for human consumption; and sells conventional Atlantic salmon, salmon eggs, fry, and byproducts.